Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 12/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 3/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 3/20 | 0.50 |
| ▸ | RXRA | P19793 | 8/20 | 0.48 |
| ▸ | RXRB | P28702 | 8/20 | 0.48 |
| ▸ | RXRG | P48443 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | C5 | P01031 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11745479 | 0.93 | RXRA (0.57) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11754360 | 0.93 | RXRA (0.57) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11752112 | 0.89 | RXRA (0.55) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11752294 | 0.89 | NR4A2 (0.59) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11747680 | 0.89 | RXRA (0.55) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11747907 | 0.89 | NR4A2 (0.50) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11752077 | 0.89 | MEN1 (0.51) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11755079 | 0.89 | CYP1A2 (0.51) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11755117 | 0.89 | NR4A2 (0.50) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11753895 | 0.89 | NR4A2 (0.50) | NR4A2MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998415-B2 | Pyrazolyl derivatives; antiinflammatory agents for inflammation; antiallergens for asthma | PHARMACIA CORPORATION (US) | 2006-02-14 | — | — | US | disclosed |
| US-20040147565-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. | 2004-07-29 | — | — | US | disclosed |
| US-6677364-B2 | ANTI-INFLAMMATORY, ANTIPYRETIC, ANALGESIC COMPOSITIONS | G.D. SEARLE & CO. | 2004-01-13 | — | — | US | disclosed |
| EP-0828736-B1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-0995747-B1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | SEARLE & CO (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020086886-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. | 2002-07-04 | — | — | US | disclosed |
| US-6090834-A | ANALGESICS; RHEUMATIC DISORDERS; SKIN DISORDERS; GASTROINTESTINAL DISORDERS | G.D. SEARLE & CO. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0995747-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0582164-B1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | BRISTOL MYERS SQUIBB CO (US) | 1998-12-23 | — | — | EP | disclosed |
| EP-0828736-A1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-03-18 | — | — | EP | disclosed |
| EP-0825989-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-03-04 | — | — | EP | disclosed |
| US-5643933-A | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G. D. SEARLE & CO. (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996038442-A1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | disclosed |
| US-5382584-A | Antiischemic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| EP-0582164-A1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | Bristol-Myers Squibb Company (US) | 1994-02-09 | — | — | EP | disclosed |
| US-4051250-A | OXAZOLE, THIAZOLE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-09-27 | — | — | US | disclosed |
| US-3933840-A | ANTIPHLOGISTIC | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147565-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX12, ALOX15 | NR4A2 655/4885MAPK13 1311/4885MAPK12 1413/4885 |
| US-20020086886-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, PTGES2, PTGS2 | NR4A2 763/4885MAPK13 2169/4885MAPK12 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.